A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology

[1]  D. Bennett,et al.  The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease , 2020, Molecular Psychiatry.

[2]  A. Ribeiro-da-Silva,et al.  Peripheral and central nervous system alterations in a rat model of inflammatory arthritis. , 2020, Pain.

[3]  J. Hort,et al.  Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice , 2020, European journal of neurology.

[4]  A. Verma,et al.  Endothelial stromelysin1 regulation by the forkhead box‐O transcription factors is crucial in the exudative phase of acute lung injury , 2019, Pharmacological research.

[5]  A. Cuello,et al.  The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology , 2019, Front. Neurosci..

[6]  E. Head,et al.  Dementia in Down syndrome: unique insights for Alzheimer disease research , 2019, Nature Reviews Neurology.

[7]  A. Pastore,et al.  The Structure of the Pro-domain of Mouse proNGF in Contact with the NGF Domain. , 2019, Structure.

[8]  E. Giacobini,et al.  Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors. , 2018, Current Alzheimer research.

[9]  for the Alzheimer’s Disease Neuroimaging Initiative,et al.  Sex differences in Alzheimer disease — the gateway to precision medicine , 2018, Nature Reviews Neurology.

[10]  L. F. Aguilar,et al.  Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease , 2017, Neurobiology of Disease.

[11]  F. Kartberg,et al.  Conformational characterization of nerve growth factor-β reveals that its regulatory pro-part domain stabilizes three loop regions in its mature part , 2017, The Journal of Biological Chemistry.

[12]  L. Moons,et al.  Mechanisms of NMDA Receptor- and Voltage-Gated L-Type Calcium Channel-Dependent Hippocampal LTP Critically Rely on Proteolysis That Is Mediated by Distinct Metalloproteinases , 2017, The Journal of Neuroscience.

[13]  P. Bosco,et al.  An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation , 2016, Alzheimer's & Dementia.

[14]  E. Mufson,et al.  Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. , 2016, Current Alzheimer research.

[15]  J. Włodarczyk,et al.  Matrix Metalloprotease 3 Activity Supports Hippocampal EPSP-to-Spike Plasticity Following Patterned Neuronal Activity via the Regulation of NMDAR Function and Calcium Flux , 2016, Molecular Neurobiology.

[16]  B. de Strooper,et al.  Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases , 2015, The Journal of Neuroscience.

[17]  M. Peng,et al.  Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease , 2015, Neuroscience Letters.

[18]  M. Witter,et al.  Stereological estimation of neuron number and plaque load in the hippocampal region of a transgenic rat model of Alzheimer's disease , 2015, The European journal of neuroscience.

[19]  X. Wang,et al.  Tumor necrosis factor-α- and interleukin-1β-dependent matrix metalloproteinase-3 expression in nucleus pulposus cells requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase-NF-κB axis: implications in inflammatory disc disease. , 2014, The American journal of pathology.

[20]  A. Cuello,et al.  Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. , 2014, Trends in pharmacological sciences.

[21]  W. Klein,et al.  Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study , 2014, Acta neuropathologica communications.

[22]  Philip S. Insel,et al.  Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults , 2014, Neurobiology of Aging.

[23]  Ashley M. Fortress,et al.  Nerve growth factor metabolic dysfunction in Down's syndrome brains. , 2014, Brain : a journal of neurology.

[24]  X. Juanola,et al.  Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis , 2014, Clinical Rheumatology.

[25]  R. Midha,et al.  Overcoming neurite‐inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix , 2013, Glia.

[26]  S. Ball,et al.  p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts , 2013, Biochemical and biophysical research communications.

[27]  K. Bötzel,et al.  Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation , 2012, Experimental Neurology.

[28]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[29]  C. Kallenberg,et al.  Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis , 2011, The Journal of Rheumatology.

[30]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[31]  S. Reina,et al.  Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. , 2011, Archives of oral biology.

[32]  Hee-Sun Kim,et al.  α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1 , 2010, The Journal of Immunology.

[33]  L. Minthon,et al.  Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease , 2010, Alzheimer's Research & Therapy.

[34]  Claudia Schilling,et al.  Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease , 2010, International Psychogeriatrics.

[35]  T. Joh,et al.  Matrix Metalloproteinase-3 Is Increased and Participates in Neuronal Apoptotic Signaling Downstream of Caspase-12 during Endoplasmic Reticulum Stress* , 2010, The Journal of Biological Chemistry.

[36]  C. Humpel,et al.  Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels , 2009, Neuroscience Letters.

[37]  J. Wuu,et al.  Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment , 2009, Journal of neuropathology and experimental neurology.

[38]  A. Cuello,et al.  Amyloid &bgr;-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease , 2009, Journal of neuropathology and experimental neurology.

[39]  A. De Couto Pita,et al.  Cholinoceptor modulation on nitric oxide regulates prostaglandin E(2) and metalloproteinase-3 production in experimentally induced inflammation of rat dental pulp. , 2009, Journal of endodontics.

[40]  G. Rosenberg,et al.  TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia , 2009, Experimental Neurology.

[41]  Hee-Sun Kim,et al.  Inhibition of MMP‐3 or ‐9 suppresses lipopolysaccharide‐induced expression of proinflammatory cytokines and iNOS in microglia , 2008, Journal of neurochemistry.

[42]  T. Joh,et al.  A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells , 2008, Journal of neurochemistry.

[43]  A. Hofman,et al.  Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease The Rotterdam Study , 2008, Neurobiology of Aging.

[44]  S. Love,et al.  MMP‐2, ‐3 and ‐9 levels and activity are not related to Aβ load in the frontal cortex in Alzheimer's disease , 2008, Neuropathology and applied neurobiology.

[45]  P. Amouyel,et al.  Impact of the matrix metalloproteinase MMP-3 on dementia , 2007, Neurobiology of Aging.

[46]  S. Lorenzl,et al.  A pivotal role of matrix metalloproteinase‐3 activity in dopaminergic neuronal degeneration via microglial activation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  M. Pizzi,et al.  Transplantation of fibroblasts that overexpress matrix metalloproteinase-3 into the site of spinal cord injury in rats. , 2006, Journal of neurotrauma.

[48]  D. Aunis,et al.  Functional interaction between matrix metalloproteinase-3 and semaphorin-3C during cortical axonal growth and guidance , 2006, International Journal of Developmental Neuroscience.

[49]  M. Moscarello,et al.  Differences in Susceptibility of MBP Charge Isomers to Digestion by Stromelysin-1 (MMP-3) and Release of an Immunodominant Epitope , 2006, Neurochemical Research.

[50]  G. Rosenberg,et al.  Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.

[51]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[52]  C. Masters,et al.  Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* , 2006, Journal of Biological Chemistry.

[53]  A. Cuello,et al.  Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Mikel L. Olson,et al.  Effects of extracellular matrix‐degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity , 2006, Journal of neurochemistry.

[55]  G. Rosenberg,et al.  Matrix metalloproteinases and free radicals in cerebral ischemia. , 2005, Free radical biology & medicine.

[56]  T. Joh,et al.  Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia , 2005, The Journal of Neuroscience.

[57]  T. Lehtimäki,et al.  Interaction between matrix metalloproteinase 3 and the ε4 allele of apolipoprotein E increases the risk of Alzheimer’s disease in Finns , 2004, Neuroscience Letters.

[58]  M. Javadi,et al.  NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. , 2004, Biochemical and biophysical research communications.

[59]  M. Moscarello,et al.  The Up-regulation of Stromelysin-1 (MMP-3) in a Spontaneously Demyelinating Transgenic Mouse Precedes Onset of Disease* , 2002, The Journal of Biological Chemistry.

[60]  M. Malaise,et al.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment , 2002, Annals of the rheumatic diseases.

[61]  Taku Sugawara,et al.  Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral Ischemia , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  B. Michalski,et al.  The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease , 2001, Molecular and Cellular Neuroscience.

[63]  M. Esiri,et al.  White Matter Damage Is Associated With Matrix Metalloproteinases in Vascular Dementia , 2001, Stroke.

[64]  A. Taniguchi,et al.  Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[65]  T. Hattori,et al.  Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain , 2000, Acta Neuropathologica.

[66]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[67]  A. Cuello,et al.  TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo , 1998, Journal of Physiology-Paris.

[68]  P. Gottschall,et al.  Increased Production of Matrix Metalloproteinases in Enriched Astrocyte and Mixed Hippocampal Cultures Treated with β‐Amyloid Peptides , 1996 .

[69]  J. Uitto,et al.  Interferon-gamma coordinately upregulates matrix metalloprotease (MMP)-1 and MMP-3, but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. , 1995, The Journal of investigative dermatology.

[70]  G. Opdenakker,et al.  Cytokine-regulated proteases in autoimmune diseases. , 1994, Immunology today.

[71]  A. Cuello,et al.  Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[73]  Y. Okada,et al.  Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. , 1987, The Journal of rheumatology.

[74]  F. Hefti,et al.  Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[75]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[76]  T. Powell,et al.  Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase , 1983, Brain Research.

[77]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[78]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[79]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[80]  C. Henneberger,et al.  Synaptic Potentiation at Basal and Apical Dendrites of Hippocampal Pyramidal Neurons Involves Activation of a Distinct Set of Extracellular and Intracellular Molecular Cues , 2019, Cerebral cortex.

[81]  G. Wilcock,et al.  Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. , 2019, Journal of Alzheimer's disease : JAD.

[82]  Pitter F. Huesgen,et al.  Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. , 2016, Matrix biology : journal of the International Society for Matrix Biology.

[83]  G. Rabinovich,et al.  The Role of Galectin-3: From Oligodendroglial Differentiation and Myelination to Demyelination and Remyelination Processes in a Cuprizone-Induced Demyelination Model. , 2016, Advances in experimental medicine and biology.

[84]  R. Bernhardi.  Glial Cells in Health and Disease of the CNS , 2016, Advances in Experimental Medicine and Biology.

[85]  M. Eriksdotter,et al.  Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. , 2014, Journal of Alzheimer's disease : JAD.

[86]  M. Hasselmo,et al.  Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition , 2011, Neuropsychopharmacology.

[87]  M. Szyf,et al.  A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[88]  A. Cuello,et al.  Cholinergic Involvement in Alzheimer’s Disease. A Link with NGF Maturation and Degradation , 2009, Journal of Molecular Neuroscience.

[89]  M. Mesulam.  The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? , 2004, Learning & memory.

[90]  T. Robbins,et al.  Central cholinergic systems and cognition. , 1997, Annual review of psychology.

[91]  A. Cuello,et al.  Chapter 32: Trophic responses of forebrain cholinergic neurons: a discussion , 1993 .

[92]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .